Beam Therapeutics shared additional data from its Phase 1/2 program of a gene editing candidate for alpha-1 antitrypsin deficiency at the ERS meeting, reporting outcomes after one year in six treated patients. The update is aimed at demonstrating durability of editing-related effects and continued safety. The asset targets a genetically driven cause of lung and liver damage, with early-stage readouts typically focused on editing performance, biomarker shifts, and tolerability. Beam’s presentation at #ERS26 underscores continued investor and clinician focus on editing strategies for monogenic diseases. For the category, longer follow-up is central to determining whether base-editing can translate into clinically meaningful, durable reductions in disease-causing protein activity over time.